Latest Cognizant Technology Solutions (CTSH)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Latest Cognizant Technology Solutions (CTSH) Headlines

Infosys Dives, Cognizant Finds Support After Warning
at Investor's Business Daily - Wed Mar 12, 6:01PM CDT
Bangalore, India-based software developer Infosys (INFY) stumbled Wednesday after management softened expectations for its fiscal fourth quarter. The stock tumbled 6%, slicing below its 10-week moving average in three times its average trade. Volume...

Stocks Open Broadly Lower; Verifone Provides A Bright Spot
at Investor's Business Daily - Wed Mar 12, 9:31AM CDT
Stocks opened to moderate losses in higher trade Wednesday as U.S. stocks reflected the day's cautious shift across global markets. All three major indexes were down 0.4%: the Nasdaq, the S&P 500 and the Dow Jones industrial average. Volume rose...

Downgrade Alert for Cognizant Technology Solutions (CTSH)
Comtex SmarTrend(R) - Wed Mar 12, 7:05AM CDT
Cognizant Technology Solutions (NASDAQ:CTSH) was downgraded from Buy to Hold at Berenberg today. The stock closed yesterday at $52.33 on volume of 3.1 million shares, above average daily volume of 2.1 million. There is potential upside of 111.1% for shares of Cognizant Technology Solutions based on a current price of $52.33 and an average consensus analyst price target of $110.45. The stock should run into initial resistance at its 200-day moving average (MA) of $83.87 and subsequent resistance at its 50-day MA of $97.95.

Look for Shares of Cognizant Technology Solutions to Potentially Rebound after Yesterday's 50.66% Sell Off
Comtex SmarTrend(R) - Mon Mar 10, 5:44PM CDT
Cognizant Technology Solutions (NASDAQ:CTSH) traded in a range yesterday that spanned from a low of $52.76 to a high of $53.51. Yesterday, the shares fell 50.7%, which took the trading range below the 3-day low of $104.50 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

SmarTrend Watching for Potential Rebound in Shares of Cognizant Technology Solutions After 50.66% Loss
Comtex SmarTrend(R) - Mon Mar 10, 5:43PM CDT
Cognizant Technology Solutions (NASDAQ:CTSH) traded in a range yesterday that spanned from a low of $52.76 to a high of $53.51. Yesterday, the shares fell 50.7%, which took the trading range below the 3-day low of $104.50 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Infosys: A Giant up from Slumber? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:56AM CST
It seems IT bellwether Infosys Technologies Ltd. is up from its deep slumber after a streak of disappointing results over the last couple of years.

Expert Briefing - New Highs: DIRECTV, Goodyear Tire & Rubber, Cognizant Technology Solutions, and Bitauto Holdings
PR Newswire - Fri Mar 07, 7:00AM CST
On Thursday, March 06, 2014, the NASDAQ Composite finished at 4,352.13, down 0.13% for the day. The Dow Jones Industrial Average closed the session at 16,421.89, up 0.38% and the S&P 500 ended the day at 1,877.03, higher by 0.17%. The gains were broad based with 7 of 10 sectors going up. Investor-Edge.com looks at some of the equities that during the last session hit a new 52-week high. These include DIRECTV (NASDAQTV), The Goodyear Tire & Rubber Co. (NASDAQ: GT), Cognizant Technology Solutions Corporation (NASDAQ: CTSH), and Bitauto Holdings Ltd (NYSE: BITA). Free research on these five companies can be accessed at:

Cognizant Technology Solutions Rises 1.37% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Mar 06, 4:19PM CST
Cognizant Technology Solutions (NASDAQ:CTSH) traded in a range yesterday that spanned from a low of $105.46 to a high of $108.00. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $105.67 on volume of 2.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Services Launches, Industry Firsts, Collaborations, and Earnings Releases - Analyst Notes on Microsoft, Cognizant, Citrix, ADP, and CA
PR Newswire - Thu Mar 06, 10:17AM CST
Editor Note: For more information about this release, please scroll to bottom.

Insider Trading Alert - ASH, WETF And CTSH Traded By Insiders
at The Street - Thu Feb 27, 10:30AM CST
Stocks with insider trader activity include ASH, WETF and CTSH

Cognizant to Present at Morgan Stanley Investor Conference
PR Newswire - Wed Feb 26, 12:34PM CST
Cognizant (NASDAQ: CTSH), a leading provider of information technology, consulting, and business process outsourcing services, today announced that Karen McLoughlin, Chief Financial Officer, will present at the following investor conference:

Accenture, IPsoft Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 5:30PM CST
Management solutions provider Accenture plc recently announced a strategic alliance with IPsoft to boost its automation capabilities.

IT Stocks: Could Outsourcing Really Be Over By 2022?
at The Street - Tue Feb 25, 4:45PM CST
James Dennin, Kapitall: Some analysts are projecting that outsourcing will wind down in 2014. What would that mean for IT stocks? In [...]

Yale prepares for atom smasher's farewell, sets stage for new physics era
M2 - Tue Feb 25, 8:45AM CST


Fallon Health Partners With Cognizant to Become the First Massachusetts Health Insurer to Provide Quotes for Merged Market Plans Under Affordable Care Act
PR Newswire - Tue Feb 25, 5:00AM CST
Cognizant (NASDAQ: CTSH) today announced that it has enabled Fallon Health, a Massachusetts-based not-for-profit health care services organization, to become the first Massachusetts health insurer to provide quotes for merged market plans mandated by the Affordable Care Act (ACA).

Cognizant Technology Solutions Set to Possibly Pullback After Yesterday's Rally of 2.06%
Comtex SmarTrend(R) - Fri Feb 21, 4:12PM CST
Cognizant Technology Solutions (NASDAQ:CTSH) traded in a range yesterday that spanned from a low of $101.07 to a high of $103.36. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $101.16 on volume of 2.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Look for Shares of Cognizant Technology Solutions to Potentially Pullback after Yesterday's 2.06% Rise
Comtex SmarTrend(R) - Fri Feb 21, 4:12PM CST
Cognizant Technology Solutions (NASDAQ:CTSH) traded in a range yesterday that spanned from a low of $101.07 to a high of $103.36. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $101.16 on volume of 2.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Cognizant Recognized in IDC MarketScape as a Leader in IT and BPO Services Across the Entire Life Sciences Value Chain: Research and Development, Manufacturing and Supply Chain, and Sales and Marketing
PR Newswire Europe - Thu Feb 20, 5:01AM CST
-- Cognizant Also Named a Leader in Strategic Consulting in Manufacturing and Supply Chain, and Sales and Marketing

Cognizant Technology Solutions (CTSH) Stock Research Links

CTSH Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 313

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 193

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 128

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 130

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 258

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 224

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 332

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 134

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 541

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Tennessee's Bold Lung Cancer Trial Signals Innovation

Updated Category News Views 161

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Continue Reading

Top 5 Most Recently Viewed Articles

Phreesia Announces Q3 Fiscal Year 2025 Financial Results

Updated Category News Views 71

Phreesia to Release Fiscal Q3 2025 Results Soon Phreesia, Inc. (NYSE: PHR) has great news for its stakeholders! The company revealed plans to announce its financial results for the third quarter of fiscal year 2025 right after market closing on a Monday in December. During this quarter, the firm experienced substantial growth and is eager to share the details with the...

Continue Reading
Innovative Water Bowl Design Enhances Pet Hydration Experience

Updated Category News Views 374

Revolutionary Pet Water Bowl Crafted for Optimal Hydration Every pet owner knows the importance of keeping their furry friends hydrated, especially during hot days. A new invention promises to enhance the experience for pets and their owners alike. This innovative water bowl, known as the THERMA DRINK, is designed with features that cater directly to pet needs. The idea...

Continue Reading
HPH's Leadership Changes Signify Strategic Direction Ahead

Updated Category News Views 177

Leadership Transitions at HPH Highest Performances Holdings Inc. (NASDAQ: HPH) has recently seen a notable change in its Board of Directors. The company announced that Mr. Peh Chin Hua's tenure as Director has come to an end, effective immediately. This decision is part of a broader strategy aimed at strengthening the Board's overall composition and capabilities. Current...

Continue Reading
Apranga Group Reports Growth in Retail Turnover for 2025

Updated Category News Views 132

Apranga Group Retail Performance Overview for 2025 Apranga Group, a major player in the retail sector, has announced its impressive financial performance for the first six months of 2025, demonstrating notable growth compared to the prior year. The company's retail turnover reached a commendable EUR 166.1 million, reflecting a 2.8% increase from the same period in 2024....

Continue Reading
IMUNON Unveils Promising New Vaccine Data for COVID-19

Updated Category News Views 154

New Vaccine Insights from IMUNON's Phase 1 Clinical Trial The innovative PlaCCine technology platform developed by IMUNON, Inc. (NASDAQ: IMNN) promises remarkable durability and advantages over traditional mRNA vaccines, particularly in the struggle against COVID-19. Robust Results from IMNN-101 Vaccine Trials In an encouraging announcement, IMUNON shared pivotal data...

Continue Reading